Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus Sintilimab in Advanced Hepatocellular Carcinoma
NCT04401813Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jun 2020
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI310 in hepatocellular carcinoma (HCC), sponsored by Innovent Biologics. Primary endpoints: Adverse Event and Objective Response Rate. Started Jun 2020; status: completed.
02
Drugs
IBI310
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04401813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401813.